Breaking Finance News

Brean Capital announced Akebia Therapeutics Inc (NASDAQ:AKBA), bumping up its stock price target to $18.00 today

Boasting a price of $9.08, Akebia Therapeutics Inc (NASDAQ:AKBA) traded 0.00% even on the day. With the last stock price close up 5.38% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Akebia Therapeutics Inc has recorded a 50-day average of $8.43 and a two hundred day average of $8.62. Volume of trade was down over the average, with 0 shares of AKBA changing hands under the typical 190,783

In a report released on 9/29/2016 Brean Capital increased the stock price target of Akebia Therapeutics Inc (NASDAQ:AKBA) to $18.00 reporting a possible upside of 0.98%.

On 03/15/2016, H.C. Wainwright released a statement for Akebia Therapeutics Inc (NASDAQ:AKBA) bumped down the target price from $25.00 to $18.00 that suggested an upside of 1.05%.

Performance Chart

Akebia Therapeutics Inc (NASDAQ:AKBA)

With a total market value of $0, Akebia Therapeutics Inc has with a one year low of $7.00 and a one year high of $13.20 .

A total of 7 equity analysts have released a ratings update on AKBA. One equity analyst rating the company a strong buy, five equity analysts rating the company a buy, one equity analyst rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $18.29.

Brief Synopsis About Akebia Therapeutics Inc (NASDAQ:AKBA)

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company's segment is the business of developing and commercializing proprietary therapeutics based on HIF biology. The Company is involved in developing its lead product candidate, vadadustat, as an oral therapy for the treatment of anemia in chronic kidney disease (CKD) subjects not on dialysis and in subjects on dialysis. Its other clinical candidate, AKB-6899, is designed as a small molecule HIF prolyl-hydroxylase (HIF-PH) inhibitor with therapeutic benefit in oncology and ophthalmology. The Company is engaged in conducting approximately two global Phase III studies for the treatment of anemia in non-dialysis dependent patients, and over two Phase III studies for the treatment of anemia in dialysis-dependent CKD patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *